Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Talen Energy Corp V.TLN


Primary Symbol: TLN

Talen Energy Corporation is an independent power producer and energy infrastructure company. The Company owns and operates approximately 10.7 gigawatts of power infrastructure in the United States, including 2.2 gigawatts of nuclear power and a significant dispatchable fossil fleet. It produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, with its generation fleet principally located in the Mid-Atlantic and Montana. Its PJM segment is engaged in electricity generation, marketing activities, commodity risk and fuel management within the PJM RTO or ISO markets and comprises Susquehanna and its natural gas and coal generation facilities. Its Other segment includes the operating and marketing activities of Montana’s proportionate share of the Colstrip Units in the WECC market, the operating activities of Nautilus, and other development activities. It owns 100% of Nautilus Cryptomine (Nautilus), a 200-megawatt bitcoin mining facility in Berwick.


NDAQ:TLN - Post by User

Bullboard Posts
Comment by everswannon Mar 09, 2009 9:21am
66 Views
Post# 15830067

RE: K-Ras 4601 _ Implication

RE: K-Ras 4601 _ Implication
Now that bigger drugs companies have identified K-ras as a biomarker for not giving Erbitux and V to their patients.

They will develop screening tests in order to identify positive K-ras patients.
That's actually great news for 4601 for 2 reasons:

1- K-Ras is now a niche market, recognized niche market
2- New testing and screening will help TLN identify their own subset of patients. Those test exist and are cheap.

This K-Ras discovery in itself reduced costs for 4601 and increase odds of success for 4601 in pancreatic and colon cancer. All this workd done by others!

The unknown pharma is probably uninterested in GBM.
Pancreatic, colon cancer will be targetted next.


Bullboard Posts